| Objective: To observe the effects of ambroxol hydrochloride combined with respiratory muscle strength training on lung function, respiratory muscle strength and serum levels of high mobility group protein 1 (HMGB1), transforming growth factor-β1 (TGF-β1) and serum amyloid?A (SAA) in elderly patients with stable stage chronic obstructive pulmonary disease (COPD). Methods: 123 elderly patients with stable stage COPD admitted to our hospital from March 2021 to April 2023 were divided into control group (ambroxol hydrochloride treatment, 61 cases) and observation group (ambroxol hydrochloride combined with respiratory muscle strength training, 62 cases) by random number table method. The efficacy, lung function, respiratory muscle strength, serum HMGB1, TGF-β1, SAA levels and adverse reactions were compared between two groups.Results: Compared with the control group of 78.69%, the clinical total effective rate of the observation group further increased by 93.55% (P<0.05). Compared with control group, the forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), FEV1/FVC, maximum expiratory pressure (MEP) and maximum inspiratory pressure (MIP) were higher in observation group at 2 months after intervention, and HMGB1, TGF-β1, and SAA were lower (P<0.05). There was no difference in the incidence of adverse reactions between two groups (P>0.05). Conclusion: Ambroxol hydrochloride combined with respiratory muscle strength training in the treatment of elderly patients with stable stage COPD, which can effectively improve the clinical treatment effect, improve the lung function and respiratory muscle strength of patients, and regulate the levels of serum HMGB1, TGF-β1 and SAA without increasing the incidence of adverse reactions. |
